Advertisement

Hormones

, Volume 14, Issue 2, pp 317–320 | Cite as

Familial partial lipodystrophy type 3: a new mutation on the PPARG gene

  • Eva Lau
  • Davide Carvalho
  • Joana Oliveira
  • Susana Fernandes
  • Paula Freitas
Letter to the Editor
  • 2 Downloads

Key words

Adipogenesis Genetic or acquired diseases Insulin resistance Lipodystrophy PPARG 

References

  1. 1.
    Garg A, Misra A, 2004 Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 33: 305–331.CrossRefGoogle Scholar
  2. 2.
    Garg A, Agarwal AK, 2009 Lipodystrophies: Disorders of adipose tissue biology. Biochim Biophys Acta 1791: 507–513.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Haque W, Shimomura I, Matsuzawa Y, Garg A, 2002 Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 87: 2395–2398.CrossRefGoogle Scholar
  4. 4.
    Peters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A, 1998 Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet 18: 292–295.CrossRefGoogle Scholar
  5. 5.
    Garg A, 2011 Lipodystrophies: Genetic and Acquired Body Fat Disorders. J Clin Endocrinol Metab 96: 3313–3325.CrossRefGoogle Scholar
  6. 6.
    Agarwal A, Garg A, 2002 A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy. J Clin Endocrinol Metab 87: 1408–1411.Google Scholar
  7. 7.
    George S, Rochford JJ, Wolfrum C, et al, 2004 A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304: 1325–1328.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rubio-Cabezas O, Puri V, Murano I, et al, 2009 Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med 1: 280–287.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gandotra S, Le Dour C, Bottomley W, et al, 2011 Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 364: 740–748.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Olofsson SO, Boström P, Andersson L, et al, 2008 Triglyceride containing lipid droplets and lipid droplet-associated proteins. Curr Opin Lipidol 19: 441–447.CrossRefGoogle Scholar
  11. 11.
    Jeninga E, Kalkhoven E, 2010 Central players in inherited lipodystrophies. Trends Endocrinol Metab 21: 581–588.CrossRefGoogle Scholar
  12. 12.
    Garg A, 2004 Acquired and inherited lipodistrophies. N Engl J Med 350: 1220–1234.CrossRefGoogle Scholar
  13. 13.
    Tan G, Savage D, Fielding B, et al, 2008 Fatty acid metabolism in patients with ppargamma mutations. J Clin Endocrinol Metab 93: 4462–4470.CrossRefGoogle Scholar
  14. 14.
    Freitas P, Santos AC, Carvalho D, et al, 2010 Fat mass ratio: an objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy. J Clin Densitom 13: 197–203.CrossRefGoogle Scholar
  15. 15.
    Vantyghem MC, Balavoine AS, Douillard C, et al, 2012 How to diagnose a lipodystrophy syndrome. Ann Endocrinol (Paris) 73: 170–189.CrossRefGoogle Scholar
  16. 16.
    Fardet L, Vigouroux C, Capeau J, 2013 Syndromes lipodystrophiques. Rev Med Interne 34: 614–622.CrossRefGoogle Scholar
  17. 17.
    Semple R, Chatterjee V, Rahilly S, 2006 PPAR-gamma and human metabolic disease. J Clin Invest 116: 581–589.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    He W, Barak Y, Hevener A, et al, 2003 Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100: 15712–15717.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Medina-Gomes G, Gray S, Vidal-Puig A, 2007 Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor g (PPARg) and PPARgcoactivator-1 (PGC1). Public Health Nutrition 10: 1132–1137.Google Scholar
  20. 20.
    Hegele R, Joy T, Al-Attar D, Rutt B, 2007 Lipodystrophies: windows on adipose biology and metabolism. J Lipid Res 48: 1433–1444.CrossRefGoogle Scholar
  21. 21.
    Visser M, Kropman E, Kranendonk, et al, 2011 Characterization of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPAR-gamma mutation (Y151C). Diabetologia 54: 1639–1644.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Semple R, Savage D, Cochran E, Gorden P, O’Rahilly S, 2011 Genetic syndromes of severe insulin resistance. Endocr Rev 32: 498–514.CrossRefGoogle Scholar
  23. 23.
    Monajemi H, Zhang L, Li G, et al, 2007 Familial Partial lipodistrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab 92: 1606–1612.CrossRefGoogle Scholar
  24. 24.
    Walker UA, Kirschfink M, Peter HH, 2003 Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation. Rheumatology 42: 393–394.CrossRefGoogle Scholar
  25. 25.
    Chong AY, Lupsa BC, Cochran EK, Gorden P, 2010 Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53: 27–35.CrossRefGoogle Scholar
  26. 26.
    Fiorenza C, Chou S, Mantzoros C, 2011 Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 7: 137–150.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2015

Authors and Affiliations

  • Eva Lau
    • 1
  • Davide Carvalho
    • 1
  • Joana Oliveira
    • 1
  • Susana Fernandes
    • 2
  • Paula Freitas
    • 1
  1. 1.Department of Endocrinology, Diabetes and Metabolism, Faculty of MedicineUniversity of Porto, Centro Hospitalar São JoãoPortoPortugal
  2. 2.Genetics Department; Faculty of MedicineUniversity of Porto, Centro Hospitalar São JoãoPortoPortugal

Personalised recommendations